Renal function in high dose chemotherapy and autologous hematopoietic cell support treatment for breast cancer
Authors:
- Elizabeth J. ShpallESElizabeth J. Shpall
- Roy B. JonesRJRoy B. Jones
- Philip G. ArcherPAPhilip G. Archer
- Robert W. SchrierRSRobert W. Schrier
- 1 September 1996
- journal article
- clinical trial
- Published by Elsevier in Kidney International
- Vol. 50 (3) , 1026-1031
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- An overview of experience with taxol∗ (paclitaxel) in the U.S.ACancer Treatment Reviews, 1993
- Veno-occlusive Disease of the Liver and Multiorgan Failure after Bone Marrow Transplantation: A Cohort Study of 355 PatientsAnnals of Internal Medicine, 1993
- Acute Renal Failure Following Bone Marrow Transplantation: A Retrospective Study of 272 PatientsAmerican Journal of Kidney Diseases, 1989
- Regimen-related toxicity in patients undergoing bone marrow transplantation.Journal of Clinical Oncology, 1988
- High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer.Journal of Clinical Oncology, 1988
- Nephrotoxicity in bone marrow transplant recipients treated with cyclpsporin ABritish Journal of Haematology, 1983
- ACUTE RENAL TOXICITY WITH COMBINED USE OF AMPHOTERICIN B AND CYCLOSPORINE AFTER MARROW TRANSPLANTATIONTransplantation, 1983
- Nephrotoxicity of nitrosoureasCancer, 1981
- A fatal case of inappropriate adh secretion induced by cyclophosphamide therapyCancer, 1979
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976